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Background: The benefits of aspirin as an anti-platelet agent are well established; however, there has been much
debate about the lack of uniformity in the efficacy of aspirin to inhibit platelet function. In some patients, aspirin
fails to inhibit platelets even where compliance has been verified, a phenomenon which has been termed “aspirin
resistance”. These patients may in turn be at a higher risk of future vascular events. The proportion of “resistant”
patients identified depends on the type of platelet function test. Therefore, the aim of this systematic review is to
determine which, if any, platelet function test has utility in terms of identifying patients with a high risk of vascular
events. The review has been registered with PROSPERO (CRD42012002151).
Methods: Relevant studies will be sought from bibliographic databases. Trials registers will be searched for ongoing
studies. Reference lists will be checked and subject experts contacted. There will be no date or language
restrictions. Standard reviewing methodology to minimise bias will be employed. Any prospective studies in
patients on aspirin therapy and assessing platelet function in relation to relevant clinical outcomes will be included,
as will studies reporting prognostic models. Risk of bias assessment will be based on the Quality Assessment of
Diagnostic Accuracy Studies guidelines, and suitable criteria for assessing quality of prognostic studies. Data on test
accuracy measures, relative risks, odds or hazard ratios will be extracted and meta-analysed, where possible, using a
random-effects model to account for between-study heterogeneity. Where appropriate, the causes of heterogeneity
will be explored through meta-regression and sub-group or sensitivity analyses. If platelet function testing is
demonstrated to have diagnostic/predictive utility in a specific population, the potential for a cost-effectiveness
analysis will be considered and, if possible, an economic model constructed. This will be supported by a systematic
review of existing economic evaluation studies.
Discussion: The results of the review could indicate if platelet function test(s) could lead to a reliable prediction of
the risk of clinically important events in a defined population, and thus support investigations into adjustments to
therapy in order to compensate for a predicted poor response to standard aspirin.
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The clinical efficacy of aspirin as an antiplatelet agent to
prevent occlusive arterial events in patients with
atherothrombotic disease is well established; daily ad-
ministration of aspirin has been shown to reduce the
risk of stroke, myocardial infarction (MI) and death by
approximately 25% [1]. Despite these proven benefits,
many patients continue to experience thrombotic events.
Several factors may influence the response of platelets to
antiplatelet therapy [2], including treatment adherence
[3]. However, in some patients even in the context of
verified compliance, aspirin fails to inhibit platelets as
determined by ex vivo laboratory tests, a phenomenon
termed “resistance” to antiplatelet therapy [4].
Many platelet function tests have been used to assess
inhibition of platelet function induced by aspirin and
their methodologies are diverse [5,6]. While some assays
study global haemostasis, most platelet function assays
target a specific phase of platelet function, from platelet
adhesion to platelet activation, secretion and aggrega-
tion [7,8]. Methodological differences make it difficult
to compare the test results. For example, some of
these assays are carried out in whole blood (including
whole blood aggregometry, platelet counting, PFA-100,
VerifyNow, Impact-R and flow cytometry), while others
require sample preparation (such as plasma or serum
thromboxane B2 measurement), and others can be per-
formed on urine (levels of the thromboxane B2 meta-
bolite 11-dehydro-thromboxane B2) [9]. Thresholds to
determine whether platelet function is within a nor-
mal range may vary between studies of the same test
depending on how the threshold was established (e.g.,
thresholds commonly reported in the literature, prescri-
bed by the manufacturer or derived from comparisons
with healthy control populations).
Most importantly, some assays are specific to the ac-
tion of aspirin, by using an agonist that targets the plate-
let pathway inhibited by aspirin (the cyclooxygenase
pathway) or by measuring metabolites of thromboxane
A2 (which is the end-product of the pathway blocked by
aspirin), while other platelet function assays assess
pathways not directly affected by aspirin but measure
global platelet reactivity [5,10,11]. The effect of aspirin
is, of course, more obvious in aspirin-specific assays, but
the global platelet reactivity assays could be more clinic-
ally relevant as they capture a more global portrait of
platelet function [12]. However, for such global assays to
be able to determine resistance to aspirin therapy would
require aspirin to be the only platelet function modifying
agent used by the patient.
There is no official guideline recommending one assay
above another, and platelet function testing is not
recommended for routine clinical testing in patients re-
quiring aspirin therapy [13]. As a result, many of theavailable platelet function assays have been used in a re-
search capacity, and part of the uncertainty surrounding
the definition and clinical relevance of aspirin resistance
is due to the non-interchangeable nature of these assays
[14]. As a consequence, there is a need to address basic
questions on the prognostic and diagnostic utility and
cost-effectiveness of platelet function testing in the con-
text of aspirin therapy before testing can be recom-
mended in clinical practice.Existing systematic reviews
Three relevant recent systematic reviews were iden-
tified, all of which included a meta-analysis [15-17].
The review by Reny et al. [17] looked at the PFA-100
test only to predict cardiovascular events in patients
with symptomatic atherosclerosis, and included 8 pro-
spective studies. A statistically significant result was
reported for an increased risk of ischemic events in
patients defined as ‘aspirin resistant’ by the test. The
other reviews included a range of platelet function
tests and identified 17 studies [15] and 20 studies [16]
respectively. Both reviews reported a statistically signi-
ficant increased risk of cardiovascular events in pa-
tients with ‘aspirin resistance’ as defined by the laboratory
test(s).
There were some methodological limitations associa-
ted with the latter two reviews, including a lack of detail
on quality assessment of included studies, the thresholds
(cut-off points) used to define ‘aspirin resistance’ for
each test, and patient compliance. The diagnostic utility
of the tests (e.g., in terms of sensitivity and specificity)
was also not considered. Further, heterogeneity between
included studies due to differences in platelet function
assays, study follow-up periods and aspirin dose, needs
to be accounted for and, where possible, investigated in
more detail. Since the completion of these reviews, sev-
eral further studies have been published, particularly due
to the emergence of dual/triple antiplatelet therapy
regimens (where aspirin is one agent) for treating some
at-risk populations with cardiovascular disease, such as
those with acute coronary syndrome or undergoing
percutaneous coronary intervention.
The aim of the current project is to perform a new
systematic review that, in comparison to existing
reviews, additionally incorporates any missed studies
and/or studies published more recently; implements a
more robust and complete meta-analysis of the evidence,
including an improved approach to quantifying and
examining clinical and statistical heterogeneity; and
summarises the evidence in relation to both prognostic
association (e.g., odds ratios, hazard ratios) and diagnos-
tic/predictive test accuracy (e.g., sensitivity, specificity)
for individual patients.
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This systematic review will look at studies which relate
platelet function testing to the risk of adverse clinical
outcome(s) in patients on aspirin therapy with
established cardiovascular or cerebrovascular disease, or
diabetes. More specifically, the review will aim to deter-
mine the diagnostic/predictive utility and the prognostic
utility of different platelet function tests:
i) Diagnostic/predictive utility:
to establish whether any of the available platelet
function tests to determine “aspirin resistance” has
sufficiently high diagnostic/predictive utility (e.g.,
sensitivity, specificity and positive and negative
predictive values close to 1) in order to determine,
for individual patients, if treatment modification
should be considered based on the test result;
ii) Prognostic utility:
to establish whether any of the available platelet
function tests has prognostic ability, i.e., whether it is
able to distinguish between groups of patients with
different average outcome risks even if it does not
accurately predict individual outcome risk.
Further, the potential for a cost-effectiveness analysis
will be considered. An economic model will be
constructed and the potential for populating the model
with data based on the results of the systematic review
explored.Methods
This protocol is registered with PROSPERO (2012:
CRD42012002151).Selection criteria
i) Diagnostic/predictive utility and prognostic utility
studiesTypes of study
Any prospective primary studies, or systematic reviews
of such studies, assessing platelet function test(s) in rela-
tion to clinical outcomes.Types of participants
Patients aged ≥18 years on aspirin (as monotherapy or
in combination with other antiplatelet agents), with
established cardiovascular or cerebrovascular disease, or
diabetes. Studies with mixed populations will be
included as long as data for relevant patients is extract-
able. Studies with patients on aspirin for peripheral vas-
cular disease will be noted.Setting
Studies in any setting will be included.
Technology
Either aspirin specific platelet function test or global
platelet function test where patients are receiving as-
pirin as the only antiplatelet therapy; or aspirin spe-
cific platelet function test where patients are on dual/
triple antiplatelet therapy (with aspirin as one of the
agents).
Outcomes
Clinical outcomes, such as: vascular events (non-fatal
and fatal ischemic stroke, transient ischemic attack, sys-
temic embolism (pulmonary embolism, peripheral arte-
rial embolism), MI, stent thrombosis); mortality due to
vascular events.
Other outcomes will include:
All-cause mortality; bleeding (categorised
according to the International Society of
Haemostasis and Thrombosis as major bleeding
events, clinically relevant non-major bleeding
events or minor bleeding events); major adverse
cardiovascular events (composite of all-
cause mortality, non-fatal MI and stroke);
revascularisation procedures (percutaneous coronary
intervention, coronary arterial bypass graft,
embolectomy).
ii) Prognostic model studies
There may be studies that report prognostic
models, in which a platelet function test is one of
multiple prognostic factors predicting clinical
outcomes in a population of interest. In order to
examine the contribution of the test to the
overall performance of the prognostic model, and
to establish whether predictive accuracy of
clinical outcomes is improved by combining test
results with other prognostic factors, the studies
will need to meet the following inclusion
criteria:i. Was a statistical model outlined to predict a relevant
clinical outcome?
ii. Did the model include a factor for platelet function
test or aspirin resistance?
iii. Was the model developed for use in
patients ≥18 years old and on aspirin (alone or in
combination with another therapy) for established
cardiovascular, cerebrovascular disease or
diabetes?
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Bibliographic databases (Cochrane Library, MEDLINE,
EMBASE) will be searched from inception to 2012.
Searches will use combinations of index and text words
that encompass the technology and the patient group
supplemented by aspirin resistance terms (see sample
MEDLINE search in Appendix 1). The ZETOC database
(British Library) and the Science Citation Index (Web of
Science) will be searched for conference proceedings.
Publicly available trials registers, such as ClinicalTrials.
gov, UK Clinical Research Network Study Portfolio
Database (UKCRN), WHO International Clinical Trials
Registry Platform and the metaRegister of Controlled
Trials (mRCT) will be searched for ongoing studies.
Reference lists of all included papers will be checked
and subject experts will be contacted. No restrictions on
publication language and date of publication will be
applied.
In addition, abstracts from the following national and
international proceedings will be consulted from 2009
onwards in order to capture studies that are not yet fully
published:
 Platelet conferences (Platelets International
Symposium);
 Cardiology conferences (British Cardiovascular
Society, American College of Cardiology (ACC),
European Society of Cardiology (ESC), American
Heart Association (AHA), American College of
Chest Physicians (ACCP));
 Stroke conferences (International Stroke
Conference, American Stroke Association);
 Haematology conferences (British Society for
Haematology, International Society on Thrombosis
and Haemostasis, International Society for
Laboratory Haematology).
Study selection
This will be a two-step process. Titles (and abstracts
where available) will initially be screened by two
reviewers, using pre-specified screening criteria. These
are broadly based on whether the studies 1) are about
platelet function testing, 2) report clinical outcomes, and
3) are in patients on aspirin therapy. Full texts of any
potentially relevant articles will then be obtained and
two reviewers will independently apply the full inclusion
criteria. Any discrepancies between reviewers will be
resolved by discussion or by referral to a third reviewer.
Appropriate portions of non-English language articles
will be translated where necessary. The study selection
process will be illustrated using a PRISMA flow diagram
[18]. Reference management software (Reference Man-
ager v11 Thomson ResearchSoft) will be used to record
reviewer decisions, including reasons for exclusion.Data extraction
Data extraction will be conducted independently by two
reviewers using a standardised, piloted data extraction
form. Disagreements will be resolved through discussion
or referral to a third reviewer.
Data extraction will include the following variables:
 Study characteristics (e.g., country, year, sample size,
number of centres);
 Study design (e.g., RCT, case-series, risk of bias);
 Patient characteristics (e.g., level of cardio- or
cerebrovascular risk in those designated aspirin
resistant or sensitive);
 Antiplatelet regimens (e.g., dose, compliance with
clinical guidelines, co-interventions, patient
adherence to treatment);
 Platelet function test utilised (e.g., thresholds, other
relevant laboratory parameters);
 Outcome measures and length of follow-up
(all vascular events, including MI, acute coronary
syndrome, ischemic stroke, transient ischemic attack
or systemic embolism, cardiovascular death, all-
cause mortality, adverse events, major and minor
bleeding; revascularisation);
 Data required to complete a 2 × 2
table (see Table 1 below), otherwise relative
risks, odds ratios or hazard ratios (with
estimates of uncertainty [19]); where sufficient
statistical information cannot be extracted, study
authors will be asked to supply necessary
information;
 Statistical methods employed and appropriateness
of these.
Data will also be extracted on any prognostic models,
including results of models reporting prognostic risk
with and without test results as a parameter.
Assessment of risk of bias
Risk of bias will be assessed independently by two revie-
wers in accordance with Quality Assessment of Diagnostic
Accuracy Studies (revised tool) (QUADAS-2) guidelines
for diagnostic test studies [20]. As there is also a prognosis
element, these guidelines will be supplemented with suita-
ble criteria for checking the quality of prognostic studies
as suggested by Hayden et al. [19]. Specific elements to be
considered include:
 Study population (adequately described, details on
sampling/recruitment);
 Study attrition (length of follow-up time, amount and
timing of censoring, reasons for loss to follow-up);
 Test measurement (adequately described, timing of
tests, missing tests results);
Table 1 A 2x2 table to be extracted from each study for
each binary outcome of interest
Test result Number of patients
with an event
Number of patients
with no events
Test positive
(‘Aspirin resistant’)
TP FP
Test negative
(‘Aspirin sensitive’)
FN TN
TP = true positives; FP = false positives; FN = false negatives; TN =
true negatives.
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unambiguously described, measured blind to the test
result);
 Statistical analysis (whether continuous tests results
were analysed on their continuous scale and, if not,
whether a non-data-dependent explanation was given
for the choice of thresholds to categorise the tests).
If any prognostic models are identified, the quality cri-
teria described by Altman et al. [21] will be used in
addition to those of Hayden et al. [19]. Specific elements
to be considered include:
 Methods of model development (selection of
candidate risk variables, relative weighting, handling
of continuous variables);
 Internal and external model validations;
 Study design (prospective/retrospective);
 Sample size (considered a priori);
 Missing data (quantity, and how missing data was
handled in the statistical analysis);
 Criteria for inclusion of prognostic factors into the
model (adequately described, and whether well-
known prognostic factors were included regardless
of significance).
Any prognostic models identified will be summarised
qualitatively (such as included variables; calculation of
risk score; predictive accuracy; whether the model was
validated internally and externally) and quantitatively by
extracting performance statistics for calibration (such as
Observed/Expected outcomes, O/E) and discrimination
(such as sensitivity and specificity) of the model.
Similarly, if prognostic models report the incremental
value of including tests, we will qualitatively summarise
the added value reported in each study (such as net re-
classification improvement, change in C statistic, etc.).
Evidence synthesis
Diagnostic/predictive utility
Where possible, meta-analysis will be applied to synthe-
sise the 2 × 2 tables from each study and produce sum-
mary estimates of test accuracy in terms of sensitivity,specificity, and positive/negative likelihood ratios for
each platelet function test (and for each threshold speci-
fied if possible). The overall prevalence (absolute risk) of
each outcome will also be summarised across studies,
alongside the outcome prevalence in each test group
separately. Analyses will be considered for a composite
endpoint of all vascular events as the primary outcome,
and then each type of vascular event individually as sec-
ondary outcomes.
A bivariate random effects meta-analysis model will be
applied, where possible, using maximum likelihood esti-
mation in STATA and Cochrane Revman (v5) software
in order to obtain the aforementioned summary
estimates of test accuracy measures. Between-study het-
erogeneity and correlation in sensitivity and specificity
caused by different study threshold choices and other
factors are accounted for in this method [22], and the
exact binomial distribution of the data correctly mod-
elled in each study [23]. Further, the summary receiver
operating characteristic (ROC) curve, positive and nega-
tive predictive values for a range of outcome
prevalences, and the summary diagnostic odds ratio will
also be estimated. In order to give a range for the sensi-
tivity and specificity of each test when applied to a spe-
cific clinical setting, 95% prediction intervals will also be
calculated.
Prognostic utility
To summarise prognostic ability, where possible a
random-effects meta-analysis model will be fitted to the
extracted data using method of moments [24] to pro-
duce summary estimates of the relative risk and odds
ratio (and their associated uncertainty) for each test.
Where studies have reported results from a ‘time-to
-event’ analysis to account for censored observations
(such as a Cox regression), hazard ratios and their
associated uncertainty will rather be extracted and then
synthesised [25]. Where possible, each threshold will be
summarised separately.
Both unadjusted and adjusted results will be extracted
from each study, and a separate meta-analysis conducted
for each where possible. Unadjusted results inform the
prognostic utility of a test when used in isolation.
Adjusted results rather reveal whether a test has prog-
nostic utility over and above other prognostic factors; a
true causal factor of poor outcome will retain strong
prognostic value even after adjustment, and so this will
also help to elicit the genuine clinical value of each test.
By default we choose a random effects meta-analysis
model to account for likely between-study heterogeneity.
Heterogeneity across studies will be measured statisti-
cally (using I2 and τ2) and examined qualitatively. Follo-
wing each random-effects meta-analysis, a 95% prediction
interval will also be calculated to estimate how the
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contexts and populations [26,27].
Where it is not appropriate to pool data, study results
will simply be tabulated and described separately.
Test for funnel plot asymmetry
For each meta-analysis of prognostic utility containing
10 or more studies, the likelihood of publication bias
will be investigated using contour-enhanced funnel
plots [28] and appropriate statistical tests (such as the
Peters Test [29]) for ‘small-study effects’; that is, the
tendency for smaller studies to provide more positive
findings [30].
Meta-regression and subgroup or sensitivity analyses
For each meta-analysis with sufficient numbers of stud-
ies (at least 10), sub-group analyses and/or meta-
regression will be used to explore whether the following
pre-specified variables explain any of the heterogeneity:
population parameters, definitions of cardiovascular
and/or cerebrovascular risk/ diabetes, aspirin dose, test
method(s), adherence to treatment, type of outcome,
length of follow up, study quality (risk of bias), and test
threshold point employed. The sensitivity of the overall
results to the inclusion/exclusion of particular studies
will be examined. Where results for multiple thresholds
exist for studies of diagnostic/predictive test accuracy,
each threshold will first be meta-analysed separately, but
then a sensitivity analysis will be undertaken according
to the multivariate modelling framework of Riley et al.
(personal communication), which analyses all thresholds
together.
The key subgroup/sensitivity analysis of interest is for
adherence to aspirin treatment. This will be achieved by
either: i) combining only those studies that present
results for patients who adhered to aspirin treatment; or
ii) performing a meta-regression where prognostic or
diagnostic utility is regressed against the proportion of
patients in each study who adhered to treatment. It is
recognised however, that meta-regression has low power
and is potentially subject to study-level confounding.
The second key subgroup/sensitivity analysis of interest
will look at the acuteness of cardiovascular disease. This
will be achieved by pooling together studies in patients
having had an acute coronary syndrome within 12
months, and those presenting with stable coronary ar-
tery disease.
Economic evaluation
Systematic review of published cost-effectiveness studies
A systematic review to identify any existing economic
studies will be undertaken, including cost analyses, cost-
effectiveness, cost-utility and cost-benefit studies, and
decision model-based analyses. Relevant outcomes will bequality-of-life, costs and incremental cost-effectiveness
ratios. Quality assessment will be appropriate to the study
design e.g. the Consensus on Health Economic Criteria
(CHEC) list [31] for economic evaluations and the Philips
checklist [32] for model-based analyses. If available, eco-
nomic models will be reviewed and utilised where appro-
priate to inform a model-based economic evaluation.
Health economic modelling
If platelet function testing is demonstrated to have diag-
nostic/predictive utility (in either the total population or
a sub-set), the construction of a cost-effectiveness model
will be considered. This will require sufficient evidence
of the clinical consequences of testing, compared to no
testing, in order to populate the model. Ideally this
requires evidence from test-treat trials (specific for a
particular test shown to have diagnostic/predictive util-
ity). If such studies exist these will be identified in the
systematic reviews above. In the absence of such studies,
evidence will have to be obtained from other sources or
simulated. The nature of any model will be dependent
on the results of the systematic review in terms of the
test(s) and population(s) in which diagnostic/predictive
utility has been deemed acceptable.
However, in the absence of strong data, a speculative
model will be constructed that could be populated with
data if future research is conducted. A speculative model
will be subject to extensive sensitivity analysis, using a
range of hypothetical values in order to demonstrate at
which point a test may become cost-effective under a
number of test-treat effectiveness assumptions.
The economic evaluation will be carried out from an
UK NHS and Personal Social Services (PSS) perspective,
to take into account health care costs and longer term
social care costs of vascular events. A Markov type, state
transition model will be the most appropriate model for
this decision problem as it can take into account
changes in health states and recurrent events over a long
period of time.
The model structure may be informed by existing
models which consider antiplatelet therapy for secondary
prevention of vascular events. If no such models are
identified, models considering other methods of second-
ary (cardiovascular disease) prevention will be sought.
The model will require data on the prognostic and diag-
nostic/predictive utility of platelet function tests and sub-
sequent interventions for therapy adjustment, including
impact on vascular events, bleeding and mortality. Data
will also be required on quality of life and health care
costs, in particular the cost of testing, drug costs and acute
and long term treatment and care of vascular events and
bleeding events. For each important model parameter, a
point estimate with a range of possible values (confidence
intervals) will be determined and a probability distribution
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ation will be based on the most likely estimates. Univariate
and probabilistic sensitivity analyses will be conducted to
deal with uncertainty in model parameters.
Discussion
It is anticipated that the results of this project will repre-
sent a significant step towards informing clinical practice
by indicating whether specific platelet function tests
have diagnostic/prognostic utility in a defined population
and could thus lead to a reasonably reliable prediction of
the risk of clinically important events. This in turn
would inform any decisions on whether platelet function
testing should be routinely used in specific populations
in order to establish a diagnosis of ‘aspirin resistance’
and would further support the investigation of candidate
adjustments to therapy to compensate for lack of re-
sponse to standard aspirin. The strength of ‘aspirin re-
sistance’ based on each test will be determined by its
diagnostic/predictive accuracy, its ability to retain prog-
nostic value even after adjustment for other factors, and
it retaining good diagnostic/predictive accuracy both in
patients who adhered to treatment and those who did
not.
If, however, the existing primary studies identified are
essentially exploratory in nature, a prospective protocol
driven hypothesis-testing study may be required before a
change in clinical practice could be justified [33-36]. The
results of the proposed review would greatly facilitate
the design of such a study. Should this review of primary
studies provide little evidence that a specific test in any
population has predictive utility, this would point to a
requirement for further improvement or refinement in
testing methods before platelet testing could be
recommended.
We do not seek individual participant data in this re-
view [33,37]. The decision to collate individual patient
data (IPD) is premature until a systematic review has
established the current reported evidence regarding the
individual prognostic and diagnostic accuracy of existing
tests, as described above. In the future, where multiple
tests are of interest in combination, for example in a
prognostic model, then collection of IPD may be more
important. However, it is first important to establish the
diagnostic/predictive/prognostic ability of individual
tests, as, if they have high diagnostic/prognostic accuracy
in defined populations, then a prognostic model includ-
ing multiple variables is potentially not necessary. Thus,
this systematic review will establish how suitable individ-
ual tests are, and identify whether subsequent research
using IPD data is suitable.
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